216 related articles for article (PubMed ID: 20070299)
1. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
Serretta V; Morgia G; Altieri V; Di Lallo A; Ruggiero G; Salzano L; Battaglia M; Falsaperla M; Zito A; Sblendorio D; Melloni D; Allegro R;
BJU Int; 2010 Jul; 106(2):212-7. PubMed ID: 20070299
[TBL] [Abstract][Full Text] [Related]
2. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
3. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
6. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
7. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
8. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Serretta V; Altieri V; Morgia G; Di Lallo A; Carrieri G; Allegro R;
Urology; 2013 Feb; 81(2):277-81. PubMed ID: 23374781
[TBL] [Abstract][Full Text] [Related]
11. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
13. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
14. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
[TBL] [Abstract][Full Text] [Related]
15. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Hinotsu S; Akaza H; Ohashi Y; Kotake T
Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
17. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
18. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
Ather MH; Aziz S; Sulaiman MN
J Ayub Med Coll Abbottabad; 2007; 19(4):18-20. PubMed ID: 18693589
[TBL] [Abstract][Full Text] [Related]
19. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
